Abstract

Cervical cancer is a significant public health concern worldwide, characterized by the uncontrolled growth of cells in the cervix, primarily caused by persistent infection with high-risk human papillomavirus (HPV). This malignancy poses a substantial burden on women's health, contributing to a significant number of cancer-related deaths, particularly in low-and middle-income countries. The development of cervical cancer is a multistep process involving various genetic and epigenetic alterations that lead to the progression from normal cervical tissue to pre-invasive lesions and ultimately invasive carcinoma. Screening programs, such as Pap smears and HPV testing have proven effective in early detection and prevention, significantly reducing the incidence and mortality associated with cervical cancer.

Advancements in understanding the molecular and cellular mechanisms underlying cervical cancer have led to the development of targeted therapies and vaccines. HPV vaccines, in particular, have demonstrated remarkable success in preventing the initial infection with high-risk HPV types, thus reducing the incidence of cervical cancer. However, challenges remain in ensuring widespread vaccine coverage, especially in resource-limited settings. Additionally, there is ongoing research to identify novel biomarkers for early detection and prognostication, as well as to elucidate the intricate interactions between the virus and the host immune system.

The management of cervical cancer involves a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy, tailored to the stage and extent of the disease. Access to timely and affordable healthcare services, along with effective prevention strategies, remains a critical factor in addressing the global impact of cervical cancer. Future research directions include refining screening methodologies, expanding vaccination efforts, and investigating new therapeutic modalities to improve outcomes for women affected by cervical cancer